The issuer is solely responsible for the content of this announcement.

The company's recent appearance at the Frankfurt Equity Forum left many strategic questions unanswered, highlighting the significant challenges Evotec faces in its future strategic positioning. Fresh ...

Analysis of Halozyme Therapeutics, Inc.'s recent developments including revenue growth, patent expiration concerns, and new ...

Halozyme made the €11-per-share offer earlier this month, valuing Evotec at around €2 billion ($2.1 billion), saying at the ...

As the signs point toward a potential Evotec acquisition, delve into what it could represent for the European biotech ...

Good morning, everyone, and welcome to another working week. We hope the weekend respite was enjoyable and invigorating, ...

Halozyme Therapeutics, a San Diego-based biopharmaceutical company, has made a $2.1 billion bid to buy German drugmaker ...

The local company announced Friday morning at 5:35 a.m. that it was withdrawing its bid to buy Evotec for about $11.52 per ...

RBC Capital analyst Charles Weston maintained a Buy rating on Evotec (0IRF – Research Report) today and set a price target of €11.60. The ...

Halozyme Therapeutics (HALO) announced it has withdrawn its non-binding proposal to acquire Evotec SE (EVO) for EUR 11.00 per share in cash, ...

Halozyme Therapeutics has pulled its proposal to buy Evotec SE for 2 billion euros ($2.09 billion) as the German drug developer was unwilling to engage in discussions, the U.S. firm said on Friday.

Halozyme stock rises after withdrawing its €2B acquisition offer for Evotec, while reaffirming strong growth outlook for 2024 ...